5-Year evaluation of electronic medical record flag alerts for patients warranting secondary prevention of coronary heart disease

Pharmacotherapy

Volumn 26, Issue 5 I, 2006, Pages 682-688

  Whitley, Heather P ^a   Fermo, Joli D ^a   Chumney, Elinor C G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cholesterol; Coronary disease; Intervention; LDL goal; Lipoproteins; Low density lipoprotein cholesterol; Pharmacist; Trials

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; DOSE CALCULATION; DRUG CONTRAINDICATION; DRUG COST; ELECTRONIC MEDICAL RECORD; EVALUATION; FEMALE; FLAG ALERT; FOLLOW UP; GOAL ATTAINMENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; POINT OF CARE TESTING; PRACTICE GUIDELINE; SIDE EFFECT; TREATMENT FAILURE; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CORONARY DISEASE; EVALUATION STUDIES; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MALE; MEDICAL AUDIT; MEDICAL RECORDS, PROBLEM-ORIENTED; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33646351021     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.5.682     Document Type: Article

References (28)

1. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham heart study. Circulation 2004;110(5):522-7.
2. Knatterud GL, Rosenberg Y, Campeau L, et al, for the Post CABG Investigators. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation 2000;102:157-65.
3. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
4. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
5. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305-10.
6. Herbert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality; an overview of randomized trials. JAMA 1997;278:313-21.
7. Sacks FM, Pfeffer MA, Moye LA, et al. The cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
8. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
9. Aengevaeren WR, Uijen GJ, Jukema JW, Bruschke AV, van der Werf T. Functional evaluation of lipid-lowering therapy by pravastatin in the regression growth evaluation statin study (REGRESS). Circulation 1997;96:429-35.
10. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;322:488-93.
11. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946-52.
12. Pendersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333-5.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
15. Cleeman JI, Lenfant C. The national cholesterol education program: progress and prospects. JAMA 1998;280:2099-104.
16. Dorak MT. Biostatistics and epidemiology. Available from: http://dorakmt.tripod.com/edi/bc/html. Accessed June 21, 2005.
17. Lictenstein AH, Ausman LM, Jalbert SM, et al. Efficacy of therapeutic lifestyle change/step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipids Res 2002;43:264-73.
18. Furmaga E. Pharmacist management of a hyperlipidemia clinic. Am J Hosp Pharm 1993;50:91-5.
19. Ito M. Should hyperlipidemia in the elderly be treated? Am J Health-Syst Pharm 1993;53:2867-71.
20. MacKinnon G. Hyperlipidemia management: opportunity for pharmacists in community practice. Pharm Times 1998;Dec:24-39.
21. Ching Lee SS, Cheung PP, Chow MS. Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong. J Clin Pharmacol 2004;44:632-9.
22. Carson J. Pharmacist-coordinated program to improve use of pharmacotherapies for reducing risk of coronary artery disease in low-income adults. Am J Health-Syst Pharm 1999;56:2319-24.
23. Shaffer J, Wexler L. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system: results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med 1995;155:2330-5.
24. Simpson SH, Johnson JA, Biggs RS, Tsuyuki RT, for the SCRIP Investigators. Greater effect of enhanced pharmacist care on cholesterol management in patients with diabetes mellitus: a planned subgroup analysis of the study of cardiovascular risk intervention by pharmacists (SCRIP). Pharmacotherapy 2004;24(3):389-94.
25. Jafari M, Masih M, Emerson JF. The value of pharmacist involvement in a point-of-care service, walk-in lipid screening program. Pharmacotherapy 2001;21(11):1403-6.
26. Kost GJ. Preventing medical errors in point-of-care-testing security, validation, performance, safeguards, and connectivity. Arch Pathol Lab Med 2001;125:1307-15.
27. Gutierres SL, Welty TE. Point-of-care testing: an introduction. Ann Pharmacother 2004;38:119-25.
28. Taylor JR, Lopez LM. Cholesterol: point-of-care testing. Ann Pharmacother 2004;38:1252-7.